We review key topics in the management of estrogen receptor (ER)–positive human epidermal growth factor receptor 2–negative breast cancer. The single biggest challenge in management of this disease is ...

SAN ANTONIO – Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance), those who displayed a rising ESR1 mutation detected in their ...

Estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2) are the mainstay of breast cancer management, and their prevalence rates vary among ...

Brussels, 6 May 2010 -- An international team of researchers has discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to drugs designed ...

Roche has reported a phase 3 win for its oral selective estrogen receptor degrader (SERD), bouncing back from an earlier setback to deliver data that could support filings for approval in breast ...

The length of a polymorphic CAG repeat in exon 1 of the androgen receptor (AR) is inversely correlated with AR transactivation activity. As heightened androgenic stimulation may oppose breast cell ...

A new study in mice provides insights into why females in their reproductive years appear to be relatively protected from chronic kidney disease, a leading public health concern. The study reports ...